30 closest matches · ranked by relevance
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Marijuana Abuse
Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants
Adolescent Methamphetamine Abuse
Primary: Feasibility of Retaining Adolescents in Trial — 33.3; 49.3 days — p=0.08
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Depression · Dual Diagnosis · Drug Addiction
Primary: Hamilton Depression Rating Scale (HAMD) Scores — 16.76; 17.65; 1.67; 16.24 score on a scale
Methamphetamine Dependence · Methamphetamine Abuse
Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses
HIV-1-infection · Methamphetamine-dependence
Primary: HIV Transcription (Cell-associated HIV RNA) in Peripheral Blood — 10.45; 57.38 copies/million cells
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Attention Deficit Hyperactivity Disorder · Nicotine Dependence · Cannabis Use Disorder
Primary: Change in ADHD Rating Scale (ADHD-RS) Total Score — -14.2; -13.8 units on a scale
Substance Abuse · HIV Infections
Primary: To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals. — 44…
Methamphetamine Dependence, Treatment Seeking
Primary: Methamphetamine Abstinence
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
ADHD · Substance Abuse
Primary: ADHD Severity — -20.6; -21.8 units on a scale
Methamphetamine Use Disorder
Primary: Number of Participants With Treatment Response During Medication Phase at Stage 1 — 10; 18; 284; 91 Participants
Methamphetamine Dependence
Primary: Methamphetamine Days of Abstinence : Proportion of Days Abstinent — .56; .55; .74; .74 proportion of days abstinent — p=.47
Methamphetamine Dependence
Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05
Substance Use Disorders
Primary: Any Cannabis Abstinence — 13; 18 participants
Depression · Substance Abuse · Substance Use
Primary: HAMD Rating Scores — 16.86; 10.71; 9.81; 7.33 Units on a scale
Methamphetamine-dependence
Primary: Functional Connectivity During Resting State Magnetic Resonance Imaging (MRI) — 0.91; 0.52; 0.54; 0.32 Fisher's Z-score
Cannabis Abuse · Cannabis Dependence
Primary: Cannabis Use — 55.89; 63.10 Percentage of use days
Methamphetamine
Primary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: End of Treatment Abstinence — 5; 4 Participants
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: Change in MA Positive Urine Drug Screens Among Participants Randomly Assigned to Receive Varenicline Versus Placebo. — 7.4; 2.3 total MA-free urine drug screens
Methamphetamine Use Disorder
Primary: Participants Categorized as "Responders" — 11 Participants
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Continuous Methamphetamine Abuse
Primary: Self-report Effects of High. — 0; 0; 0; 0 units on a scale
Stimulant Dependence · Methamphetamine-dependence · Addiction, Drug
Primary: Retention in the Study — 28.2; 45.4 Days — p=0.1760
Substance Abuse · HIV Infections
Primary: Feasibility: Proportion of Persons Screened Who Are Eligible and Enrolled — 30 Eligible persons screened who enrolled